The Lipoprotein(a) Hypothesis Takes a Hit The pharmaceutical industry's multibillion dollar gamble on reducing lipoprotein(a), or Lp(a), levels has hit a snag, and the implications are far reaching.
Novartis' failure in a closely watched cardiovascular trial with its pelacarsen drug has sent shockwaves through Wall Street and beyond.
Lp(a) is a particularly pernicious form of cholesterol that elevates cardiovascular risks and affects roughly one in five people worldwide.